Literature DB >> 17188620

Bone mineral density in children and adolescents with neurofibromatosis type 1.

David A Stevenson1, Laurie J Moyer-Mileur, Mary Murray, Hillarie Slater, Xiaoming Sheng, John C Carey, Bukhosi Dube, David H Viskochil.   

Abstract

OBJECTIVE: To assess whether children and adolescents with neurofibromatosis type 1 (NF1) have decreased bone mineral density (BMD). STUDY
DESIGN: Bone densitometry of the whole body, hip, and lumbar spine was used in a case-to-control design (84 individuals with NF1: 293 healthy individuals without NF1). Subjects were 5 to 18 years old. Subjects with NF1 were compared with control subjects by using an analysis-of-covariance with a fixed set of covariates (age, weight, height, Tanner stage, and sex).
RESULTS: Subjects with NF1 had decreased areal BMD (aBMD) of the hip (P <.0001), femoral neck (P <.0001), lumbar spine (P = .0025), and whole body subtotal (P <.0001). When subjects with NF1 were separated in groups with and without a skeletal abnormality, those who did not have a skeletal abnormality still had statistically significant decreases in aBMD compared with control subjects (P <.0001 for whole body subtotal aBMD), although they were less pronounced than in those with osseous abnormalities.
CONCLUSIONS: These data suggest that individuals with NF1 have a unique generalized skeletal dysplasia, predisposing them to localized osseous defects. Dual energy x-ray absorptiometry may prove useful in identifying individuals with NF1 who are at risk for clinical osseous complications and monitoring therapeutic trials.

Entities:  

Mesh:

Year:  2007        PMID: 17188620      PMCID: PMC1808316          DOI: 10.1016/j.jpeds.2006.10.048

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  32 in total

1.  Neurofibromatosis 1: clinical review and exceptions to the rules.

Authors:  Helen Young; Shelley Hyman; Kathryn North
Journal:  J Child Neurol       Date:  2002-08       Impact factor: 1.987

2.  Decreased bone mineral density in neurofibromatosis-1 patients with spinal deformities.

Authors:  T Illés; V Halmai; T de Jonge; J Dubousset
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

3.  Performance of a new pubertal self-assessment questionnaire: a preliminary study.

Authors:  S J Taylor; P H Whincup; P C Hindmarsh; F Lampe; K Odoki; D G Cook
Journal:  Paediatr Perinat Epidemiol       Date:  2001-01       Impact factor: 3.980

4.  Vitamin D deficiency associated with number of neurofibromas in neurofibromatosis 1.

Authors:  M Lammert; J M Friedman; H J Roth; R E Friedrich; L Kluwe; D Atkins; T Schooler; V-F Mautner
Journal:  J Med Genet       Date:  2006-03-29       Impact factor: 6.318

5.  Z score prediction model for assessment of bone mineral content in pediatric diseases.

Authors:  K J Ellis; R J Shypailo; D S Hardin; M D Perez; K J Motil; W W Wong; S A Abrams
Journal:  J Bone Miner Res       Date:  2001-09       Impact factor: 6.741

6.  Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body.

Authors:  T Kuorilehto; M Pöyhönen; R Bloigu; J Heikkinen; K Väänänen; Juha Peltonen
Journal:  Osteoporos Int       Date:  2004-11-16       Impact factor: 4.507

7.  Decreased bone mineral density in patients with neurofibromatosis 1.

Authors:  Marga Lammert; Martin Kappler; Victor-Felix Mautner; Kurt Lammert; Stephan Störkel; Jan M Friedman; Derek Atkins
Journal:  Osteoporos Int       Date:  2005-06-30       Impact factor: 4.507

8.  Alleles of RUNX2/CBFA1 gene are associated with differences in bone mineral density and risk of fracture.

Authors:  Tanya Vaughan; Julie A Pasco; Mark A Kotowicz; Geoff C Nicholson; Nigel A Morrison
Journal:  J Bone Miner Res       Date:  2002-08       Impact factor: 6.741

9.  Muscle size, strength, and bone geometry in the upper limbs of young and old men.

Authors:  C S Klein; B L Allman; G D Marsh; C L Rice
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2002-07       Impact factor: 6.053

10.  Orthopaedic manifestations of neurofibromatosis in children: an update.

Authors:  Michael G Vitale; Abhijit Guha; David L Skaggs
Journal:  Clin Orthop Relat Res       Date:  2002-08       Impact factor: 4.176

View more
  33 in total

1.  Skeletal manifestations in pediatric and adult patients with Niemann Pick disease type B.

Authors:  Melissa Wasserstein; James Godbold; Margaret M McGovern
Journal:  J Inherit Metab Dis       Date:  2012-06-21       Impact factor: 4.982

2.  Neurofibromatosis: chronological history and current issues.

Authors:  João Roberto Antônio; Eny Maria Goloni-Bertollo; Lívia Arroyo Trídico
Journal:  An Bras Dermatol       Date:  2013 May-Jun       Impact factor: 1.896

Review 3.  When Low Bone Mineral Density and Fractures Is Not Osteoporosis.

Authors:  Smita Jha; Marquis Chapman; Kelly Roszko
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

4.  Bone resorption in syndromes of the Ras/MAPK pathway.

Authors:  D A Stevenson; E L Schwarz; J C Carey; D H Viskochil; H Hanson; S Bauer; H-Y Cindy Weng; T Greene; K Reinker; J Swensen; R J Chan; F-C Yang; L Senbanjo; Z Yang; R Mao; M Pasquali
Journal:  Clin Genet       Date:  2011-01-19       Impact factor: 4.438

5.  Pediatric 25-hydroxyvitamin D concentrations in neurofibromatosis type 1.

Authors:  David A Stevenson; David H Viskochil; John C Carey; Xiaoming Sheng; Mary Murray; Laurie Moyer-Mileur; Judd Shelton; William L Roberts; Ashley M Bunker; Heather Hanson; Stephanie Bauer; Jacques L D'Astous
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

6.  Successful treatment of congenital pseudarthrosis of the tibia: still a challenge.

Authors:  K Bobotas; S N Lallos; V S Nikolaou; D S Kοrres; N E Efstathopoulos
Journal:  Eur J Orthop Surg Traumatol       Date:  2012-09-02

7.  Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis.

Authors:  Steven D Rhodes; Hao Yang; Ruizhi Dong; Keshav Menon; Yongzheng He; Zhaomin Li; Shi Chen; Karl W Staser; Li Jiang; Xiaohua Wu; Xianlin Yang; Xianghong Peng; Khalid S Mohammad; Theresa A Guise; Mingjiang Xu; Feng-Chun Yang
Journal:  J Bone Miner Res       Date:  2015-05-21       Impact factor: 6.741

Review 8.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

9.  Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.

Authors:  Steven D Rhodes; Xiaohua Wu; Yongzheng He; Shi Chen; Hao Yang; Karl W Staser; Jiapeng Wang; Ping Zhang; Chang Jiang; Hiroki Yokota; Ruizhi Dong; Xianghong Peng; Xianlin Yang; Sreemala Murthy; Mohamad Azhar; Khalid S Mohammad; Mingjiang Xu; Theresa A Guise; Feng-Chun Yang
Journal:  J Bone Miner Res       Date:  2013-12       Impact factor: 6.741

10.  Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.

Authors:  Richa Sharma; Xiaohua Wu; Steven D Rhodes; Shi Chen; Yongzheng He; Jin Yuan; Jiliang Li; Xianlin Yang; Xiaohong Li; Li Jiang; Edward T Kim; David A Stevenson; David Viskochil; Mingjiang Xu; Feng-Chun Yang
Journal:  Hum Mol Genet       Date:  2013-07-17       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.